Developing mRNA stability assay system services is core to addressing the fact that mRNA stability regulation is a key means of controlling gene expression during physiological transition and regulatory processes. Existing detection methods (such as Actinomycin D assay, kinetic labeling technology, c-fos serum-inducible system, and Tet-off regulatory promoter system) have potential limitations, including high technical requirements, long time consumption, and possible alterations to cellular physiological states. Meanwhile, mRNA drugs vary in application scenarios and specific needs, necessitating tailored assay solutions.
As a global leader in mRNA stability detection, Creative Biolabs, leveraging years of experience and advanced technology platforms, can overcome the limitations of existing methods through this service, deliver customized solutions aligned with clients' specific requirements, support the smooth progression of their projects, and provide reliable backing for mRNA drug development and related endeavors.
Discover How We Can Help - Request a Consultation Today
Modern biopharmaceuticals demand highly specific and sensitive detection methods to accurately profile degradation. Our services cover various factors and methodologies crucial for full stability characterization.
| Detection Target Category | Specific Detection Indicator | Description |
|---|---|---|
| Core Kinetic Metrics | mRNA Half-Life | The key indicator for measuring mRNA stability refers to the time required for 50% of the target mRNA to degrade after transcriptional shut-off. |
| Decay Rate Constant | A quantitative parameter defining the speed of mRNA degradation, providing data support for dynamic modeling of gene expression. | |
| Degradation Mechanism-Related Metrics | poly(A) Tail Shortening Kinetics | Tracks the initial rate-limiting step of mRNA degradation, clarifying the role of deadenylases in the degradation process. |
| Degradation Intermediate Characteristics | Analyzes mRNA degradation pathways (e.g., nuclease cleavage sites, degradation fragment types) by detecting fragments generated during degradation. | |
| Expression & System Validity Metrics | Relative mRNA Abundance | Baseline expression level before transcriptional repression, verifying the activation efficiency and stability of the detection system. |
| Expression Homogeneity | Analyzes intercellular differences in mRNA expression to ensure the reliability of stable cell lines or detection systems. | |
| Application-Scenario Adapted Metrics | Formulation Stability-Related Indicators | Changes in mRNA integrity under different storage conditions (e.g., temperature, freeze-thaw cycles) guide formulation optimization and determination of storage conditions. |
| Functional Correlation Indicator | Establishes a link between mRNA stability and final therapeutic function by combining with protein expression levels, verifying the practical value of detection data. |
Our process is designed to be highly transparent and tailored, ensuring the generated assays are perfectly suited to your specific molecule and intended application.
Inducing controlled degradation (e.g., accelerated aging via temperature ramps, exposure to proteases/nucleases, pH stress) to generate reference degraded samples.
Selecting the most appropriate analytical technology (e.g., HPLC, DUVRR, DLS, or ELISA) based on the client's CQA, target molecule, and desired detection limits.
Fine-tuning parameters for each assay, including concentration limits, reagent compatibility, and calibration using established standards. For advanced methods like DUVRR, this involves optimizing the laser wavelength and spectral acquisition parameters.
Rigorous testing for accuracy, precision, linearity, and robustness according to ICH Q2(R1) guidelines. This confirms the assay's suitability for regulatory submission.
Seamless transfer of the developed assay, including on-site training and documentation, allowing the client to implement the test in-house or with a contract manufacturer.
Estimated Timeframe:
The typical timeframe for the end-to-end assay development and validation ranges from 10 to 18 weeks, depending primarily on the molecule's structural complexity and the number of degradation pathways that require monitoring.
As biology experts, you require more than just data—you need predictive, non-destructive tools that secure your therapeutic pipeline. Creative Biolabs understands that every molecule presents a unique stability challenge. We promote our Stability Evaluation Assay Development Service as your indispensable partner, providing customized, high-resolution analytical solutions that are built for regulatory success.
End-to-end stability assay development, from initial feasibility studies to full, regulatory-compliant validation, ensuring the assay is perfectly suited to your specific drug molecule.
Implementation of Deep-UV Resonance Raman (DUVRR) Spectroscopy for rapid, in situ, label-free monitoring of nucleic acid integrity (essential for mRNA-based therapeutics).
Integrated analysis combining Physical (DLS/SEC-MALS), Chemical (LC-MS/MS), and Functional (Cell-based Potency) methods for holistic stability profiling.
Specialized assay protocols developed to overcome analytical interference from complex delivery systems, particularly Lipid Nanoparticles (LNPs) and viral vectors.
All method validation and qualification rigorously performed according to ICH Q2(R1) Guidelines, guaranteeing regulatory submission readiness.
Provision of detailed SOPs and hands-on support to ensure the successful implementation of the validated assay within your internal Quality Control QC laboratory.
Experience the Creative Biolabs Advantage - Get a Quote Today!
Our deep expertise in spectroscopic methods, including DUVRR, is specifically designed to overcome interference from complex matrices like LNPs, enabling highly sensitive and specific analysis of the encapsulated cargo (e.g., mRNA) without sample destruction.
Assay development (the core method setup) generally takes 6-10 weeks, while the full, regulatory-compliant validation (ICH Q2(R1)) typically adds another 4-8 weeks, depending on the number of parameters to be validated.
They are designed for both. Early-stage projects benefit from the high-throughput screening capacity and real-time feedback, allowing for rapid formulation optimization. Late-stage projects rely on the same assays after full qualification and validation for IND/BLA submissions.
While we utilize standard techniques for orthogonal validation, our strength lies in advanced methods like DUVRR, which offers in situ analysis that standard destructive methods cannot. This non-destructive, real-time analysis provides a significant advantage in monitoring stability kinetics and minimizing sample usage.
Absolutely. Assay transfer is a core part of our service. We provide comprehensive SOPs, validation reports, and on-site training to ensure your QC team can seamlessly implement and execute the final, validated assay with confidence.
Creative Biolabs offers the industry's most advanced and reliable Stability Evaluation Assay Development Service, utilizing cutting-edge techniques like DUVRR spectroscopy and rigorous validation processes. We are dedicated to delivering the high-quality, regulatory-ready data you need to ensure the longevity and safety of your biopharmaceutical product.
Contact Our Team for More Information and to Discuss Your Project
